Merkel Cell Carcinoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Merkel Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, ultraviolet exposure, and immune suppression. Symptoms include painless nodules on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatments include chemotherapy, radiation therapy, and surgery.
The Merkel Cell Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Merkel Cell Carcinoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 70 molecules, with 67 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Merkel Cell Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Merkel Cell Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Merkel Cell Carcinoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
23andMe Holding CoAffini-T Therapeutics Inc
Alphamab Oncology
Amgen Inc
Apcure SAS
Arcus Biosciences Inc
Ascendis Pharma AS
Aulos Bioscience Inc
Bavarian Nordic AS
BeiGene Ltd
Beijing Advaccine Biotechnology Company Ltd
BeyondSpring Inc
BioInvent International AB
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
CanWell Pharma Inc
Centrymed Pharmaceutical Inc
Checkpoint Therapeutics Inc
CStone Pharmaceuticals Co Ltd
Curadev Pharma Pvt Ltd
CytomX Therapeutics Inc
Eikon Therapeutics Inc
Eisai Co Ltd
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Geistlich Pharma AG
GI Innovation Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Immune Onc Therapeutics Inc
ImmunityBio Inc
Immunomic Therapeutics Inc
IMVAQ Therapeutics Corp
Incyte Corp
JSR Life Sciences LLC
Kartos Therapeutics Inc
Kymera Therapeutics Inc
Marengo Therapeutics Inc
Mayo Clinic
Medicenna Therapeutics Corp
Memgen Inc
Merck & Co Inc
Merck KGaA
Morphogenesis Inc
NeoImmuneTech Inc
Ocellaris Pharma Inc
Oncovir Inc
Osaka University
Philogen SpA
Phio Pharmaceuticals Corp
PokeAcell
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Simcha Therapeutics Inc
SOTIO Biotech AS
Treadwell Therapeutics Inc
University of Pittsburgh
Xencor Inc
Zai Lab Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Merkel Cell Carcinoma reports